Midatech Pharma PLC Announces MTX110 presented at 2020 Annual SNO Conference

Rhea-AI Summary

Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP) announced the presentation of research on MTX110 at the recent Society of Neuro-Oncology conference (SNO2020). The studies included a Phase I/II trial of MTX110 for DIPG and its efficacy in adult glioblastoma models. Steve Damment, EVP R&D, highlighted the promising results from the Phase I trial and preclinical data supporting MTX110's potential. MTX110, a water-soluble panobinostat, utilizes a specialized delivery method to enhance drug concentration at tumor sites while minimizing systemic effects. For more details, visit the company's website.

Positive

• Promising results from Phase I trial on MTX110 for DIPG presented at SNO2020.
• Encouraging preclinical data on MTX110's efficacy in adult glioblastoma.
• MTX110 utilizes innovative delivery methods, enhancing drug concentration at tumor sites.

Negative

• None.

ABINGDON, OXFORDSHIRE / ACCESSWIRE / November 24, 2020 / Midatech Pharma PLC (AIM:MTPH.L)(NASDAQ:MTP), an R&D biotechnology company focused on improving the bio-delivery and biodistribution of medicines, is pleased to note that the latest research on MTX110 was presented by its collaborators at the recent annual meeting of the Society of Neuro-Oncology (SNO2020 Virtual Conference). Links to the Abstracts and Posters are provided below:

PNOC015: An Open Label Single Arm Phase I/II Study of MTX110 Delivered by Convection-Enhanced Delivery (CED) in Patients with Diffuse Intrinsic Pontine Glioma (DIPG) Previously Treated with External Beam Radiation Therapy (ABSTRACT DDRE-21) - Lead Author: Dr Sabine Mueller, Pacific Pediatric Neuro-Oncology Consortium

The Abstract may be found at: https://academic.oup.com/neuro-oncology/article-abstract/22/Supplement_2/ii66/5960703?redirectedFrom=fulltext

The Poster may be found at: http://midatechpharma.com/uploads/pdf/pnoc015.pdf

Efficacy of Soluble Panobinostat (MTX110) in Preclinical Models of Adult Glioblastoma (ABSTRACT TMOD-27) - Lead Author: Dr David Ashley, Preston Tisch Brain Tumor Centre, Duke University, Durham NC 27710

The Abstract may be found at: https://academic.oup.com/neuro-oncology/article-abstract/22/Supplement_2/ii233/5961404?redirectedFrom=fulltext

The Poster may be found at: http://midatechpharma.com/uploads/pdf/Conlon-TMOD27.pdf

Commenting, Steve Damment, EVP R&D of Midatech, said: "These presentations provide further information on the encouraging Phase I DIPG trial results recently announced by Midatech on 19 October 2020, and preclinical efficacy data supporting the potential utility of MTX110 for the significantly larger adult glioblastoma indication."

About MTX110
MTX110 is a water-soluble form of panobinostat free base, achieved through complexation with hydroxypropyl-β-cyclodextrin (HPBCD), that enables convection-enhanced delivery (CED) at potentially chemotherapeutic doses directly to the site of the tumour. Panobinostat is a hydroxamic acid and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor). The currently available oral formulation of panobinostat lactate (Farydak®) is not suitable for treatment of brain cancers owing to poor blood-brain barrier penetration and inadequate brain drug concentrations. Based on favourable translational science data, MTX110 is being evaluated clinically as a treatment for DIPG (NCT03566199, NCT04264143) and recurrent medulloblastoma (NCT04315064), and preclinically for treatment of glioblastoma (SNO 2020 Abstract TMOD-27). MTX110 is delivered directly into and around the patient's tumour via a catheter system (e.g. CED or fourth ventricle infusions) to bypass the blood-brain barrier. This technique exposes the tumour to very high drug concentrations while simultaneously minimising systemic drug levels and the potential for toxicity and other side effects. Panobinostat has demonstrated high potency against DIPG tumour cells in in vitro and in vivo models, and in a key study it was the most promising of 83 anticancer agents tested in 14 patient-derived DIPG cell lines (Grasso et al, 2015. Nature Medicine 21(6), 555-559).

For more information, please contact:

Midatech Pharma PLC

Stephen Stamp, CEO, CFO Steve Damment, EVP R&D

Tel: +44 (0)29 20480 180

www.midatechpharma.com

Panmure Gordon (UK) Limited (Nominated Adviser and Joint Broker)

Freddy Crossley, Emma Earl (Corporate Finance)

Rupert Dearden (Corporate Broking)

Tel: +44 (0)20 7886 2500

Turner Pope Investments (TPI) Limited (Joint Broker)

Andrew Thacker (Corporate Broking) Tel: +44 (0)20 3657 0050

IFC Advisory Limited (Financial PR and UK Investor Relations)

Tim Metcalfe / Graham Herring

Tel: +44 (0)20 3934 6630

Email: midatech@investor-focus.co.uk

Edison Group (US Investor Relations) Megan Paul Tel: +1 (646) 653 7034 Email: mpaul@edisongroup.com

About Midatech Pharma PLC Midatech Pharma PLC (dual-listed on LSE AIM:MTPH; and NASDAQ:MTP) is a drug delivery technology company focused on improving the bio-delivery and bio-distribution of medicines. The Company combines approved and development medications with its proprietary and innovative drug delivery technologies to provide compelling products that have the potential to powerfully impact the lives of patients. The Company has developed three in-house technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's technologies have successfully entered human use in the clinic, providing important validation of the potential for each platform: · Q-Sphera™ platform: a disruptive micro-technology used for sustained release to prolong and control the release of therapeutics over an extended period of time (from weeks to months). · MidaSolve™ platform: an innovative nanotechnology used to dissolve insoluble drugs so that they can be administered in liquid form directly and locally into tumours. · MidaCore™ platform: a leading-edge nanotechnology used for targeting medications to sites of disease. The platform nature of the technologies offers the potential to develop multiple drug assets rather than being reliant on a limited number of programmes. Midatech's technologies are supported by 36 patent families including 120 granted patents and an additional 70 patent applications. Midatech's headquarters and R&D facility is in Cardiff, UK. For more information please visit www.midatechpharma.com

Forward-Looking Statements
Certain statements in this press release may constitute "forward-looking statements" within the meaning of legislation in the United Kingdom and/or United States Private Securities Litigation Reform Act. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements.

Reference should be made to those documents that Midatech shall file from time to time or announcements that may be made by Midatech in accordance with the London Stock Exchange AIM Rules for Companies ("AIM Rules"), the Disclosure and Transparency Rules ("DTRs") and the rules and regulations promulgated by the US Securities and Exchange Commission, which contains and identifies other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Midatech are expressly qualified in their entirety by the cautionary statements above. Except as may be required under the AIM Rules or the DTRs or by relevant law in the United Kingdom or the United States, Midatech does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or otherwise arising.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

SOURCE: Midatech Pharma PLC

View source version on accesswire.com:
https://www.accesswire.com/618087/Midatech-Pharma-PLC-Announces-MTX110-presented-at-2020-Annual-SNO-Conference

FAQ

What was presented at the SNO2020 conference regarding MTP stock?

Midatech Pharma presented research on MTX110, highlighting its Phase I trial results for DIPG and preclinical efficacy in glioblastoma.

What is MTX110's significance in cancer treatment for MTP?

MTX110 is a water-soluble form of panobinostat, designed for effective delivery to brain tumors, improving treatment outcomes.

When were the Phase I results for MTX110 announced?

The Phase I results for MTX110 were announced on October 19, 2020.

How does MTX110 improve drug delivery for brain cancer?

MTX110 uses convection-enhanced delivery to bypass the blood-brain barrier, allowing high drug concentrations directly at tumor sites.

What are the future prospects for MTX110 according to Midatech Pharma?

Midatech Pharma sees potential for MTX110 in treating DIPG and recurrent medulloblastoma based on supportive clinical and preclinical data.